Update on biomarkers in psoriatic arthritis

被引：30

作者：

Chandran V. ^{[1
]}

Gladman D.D. ^{[1
]}

机构：

[1] Department of Medicine, University of Toronto, Toronto Western Hospital, Toronto, ON M5T 2S8, 399 Bathurst Street

来源：

Current Rheumatology Reports | 2010年 / 12卷 / 4期

基金：

加拿大健康研究院;

关键词：

Biomarkers; Gene; Joint damage; Osteoclast precursors; Psoriasis; Psoriatic arthritis; Screening;

D O I：

10.1007/s11926-010-0107-0

中图分类号：

学科分类号：

摘要：

Biomarkers in psoriatic arthritis (PsA) may serve as surrogate end points for disease outcome and can provide insights into disease susceptibility and natural history. Biomarkers could relate to diagnosis, pathogenesis, prognosis, therapeutic response, and comorbidities. The "felt need" is, however, in the development of biomarkers for the presence of PsA in patients with psoriasis, as well as that for joint damage. During the past few years, many studies related to PsA biomarkers have been conducted. These studies are reviewed here. C-reactive protein, matrix metalloproteinase-3, and circulating osteoclast precursors show promise. An international goal-directed study to determine biomarkers for joint damage in PsA is now under way through a collaborative effort of GRAPPA (the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis) and OMERACT (Outcome Measures for Rheumatology Clinical Trials). © 2010 Springer Science+Business Media, LLC.

引用

页码：288 / 294

页数：6

共 52 条

[1]

Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework, Clin Pharmacol Ther, 69, pp. 89-95, (2001)

[2]

Wright V., Moll J.M.H., Psoriatic arthritis, Seronegative Polyarthritis, pp. 169-223, (1976)

[3]

Taylor W., Gladman D., Helliwell P., Classification criteria for psoriatic arthritis: Development of new criteria from a large international study, Arthritis Rheum, 54, pp. 2665-2673, (2006)

[4]

Fitzgerald O., Winchester R., Psoriatic arthritis: From pathogenesis to therapy, Arthritis Res Ther, 11, (2009)

[5]

Gladman D.D., Antoni C., Mease P., Et al., Psoriatic arthritis: Epidemiology, clinical features, course, and outcome, Ann Rheum Dis, 64, SUPPL. 2, (2005)

[6]

Gladman D.D., Natural history of psoriatic arthritis, Baillieres Clin Rheumatol, 8, pp. 379-394, (1994)

[7]

Fransen J., Antoni C., Mease P.J., Et al., Performance of response criteria for assessing peripheral arthritis in patients with psoriatic arthritis: Analysis of data from randomised controlled trials of two tumour necrosis factor inhibitors, Ann Rheum Dis, 65, pp. 1373-1378, (2006)

[8]

Ho P.Y., Barton A., Worthington J., Et al., Investigating the role of the HLA-Cw 06 and HLA-DRB1 genes in susceptibility to psoriatic arthritis: Comparison with psoriasis and undifferentiated inflammatory arthritis, Ann Rheum Dis, 67, pp. 677-682, (2008)

[9]

Cargill M., Schrodi S.J., Chang M., Et al., A large-scale genetic association study confirms IL12B and leads to the identification of IL23R as psoriasis-risk genes, Am J Hum Genet, 80, pp. 273-290, (2007)

[10]

Nair R.P., Duffin K.C., Helms C., Genome-wide scan reveals association of psoriasis with IL-23 and NF-kappaB pathways, Nat Genet, 41, pp. 199-204, (2009)

← 1 2 3 4 5 6 →